September 26, 2020
Add to Twitter
English | عربي
Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD
• Divestiture strategy on track • Portfolio includes prescription products in Takeda’s Cardiovascular/Metabolic and Anti-inflammatory therapeutic areas along with Calcium

News Agencies Feed